Naslov
The impact of imipenem consumption on resistance rate.

Autori
Schonwald, Slavko ; Bagatin, J ; Baršić, Bruno ; božinović, D ; Golubović, V ; Francetić, Igor ; Houra, Zlatko ; Jajić Benčić, Ines ; Kalenić, Smilja ; Labar, Boris ; Maldini, Branka ; Novak, M ; Perić, Mladen ; Punda, Volga ; Samaržija, M ; Škrlin, Jasenka ; Tambić, Arjana ; Tepeš-Kučišec, Nastja ; Vucić, N ; Vuković, Dubravka ; Zdunić, I.

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni

Izvornik
Abstracts of 'nems 2001. / - Venecija, 2001

Skup
First internatinal meeting of penems, carbapenems, and related compounds

Mjesto i datum
Venecija, Italija, 13.12.2001. - 15.12.2001

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
imipenem; consumption; resistance

Sažetak
The consumption rates in relation to the resistance onset was monitored. The monitoring the consumption rates was conducted in 12 ICU-s throughout the Croatia. Imipenem/cilastatin consumption was expressed in Defined Daily Doses (DDD) and the resistance rate was monitored in all gram negative bacteria, especially in Pseudomonas aeruginosa. The results of resistance rate monitoring were analyzed every six months in the period from 1998-2000. Results. Figure 1 presents the least favourable ratio between antibiotic consumption and resistance rate. Obtained data showed that resistance to P. aeruginosa increased in parallel with the increase in the antibiotic consumption. Figure 2 shows the most favourable ratio where resistance rate decreased with significantly increased consumption rate. Figure 3 presents mean values of results obtained in all ICUs in the observed period, indicating that the increase in the consumption rates does not follow the occurrence of resistance. A three year monitoring of antibiotic consumption and resistance rates in ICUs in patients with severe infections treated with imipenem/cilastatin proved very successful. During imipenem/cilastatin administration a special attention was given to dosage regimen and treatment duration so that the patients wouldn't be overdosed or the duration of therapy too short, which is one of the common factors for the deveelopment of resistance. Thanks to adequate therapy implemented, we can conclude that during the observed period, there was no increase in the resistance rates recorded with regards to the increase of imipenem/cilastatin consumption. The monitoring is continued.

Izvorni jezik
Engleski

POVEZANOST RADA